ziltivekimab   Click here for help

GtoPdb Ligand ID: 11552

Synonyms: COR-001 | COR001 | MEDI-5117 | MEDI5117 | ZILTI
Immunopharmacology Ligand
Compound class: Antibody
Comment: Ziltivekimab (MEDI5117) is a humanized monoclonal antibody directed against the IL-6 ligand. It was developed to inhibit pro-inflammatory IL-6 signalling in conditions that are associated with systemic inflammation, including atherosclerosis, chronic kidney disease, and rheumatoid arthritis [2], and it has also been explored for anti-tumour activity [6]. The Fc domain of ziltivekimab has been engineered to extend its half-life (by increasing affinity for FcRn), to support once-monthly administration [1].
Click here for help
No information available.
Summary of Clinical Use Click here for help
Ziltivekimab (MEDI5117) has been investigated in trials of patients with rheumatoid arthritis, and was progressed to studies for conditions that are driven in part by chronic inflammation (e.g. atherosclerotic cardiovascular disease). In fall 2026, Novo Nordisk announced that they were stopping two phase 3 studies (known as the HERMES and ATHENA trials) in heart failure, early, following the failure of the ZEUS study to meet its primary endpoint (significant reduction in the risk of major adverse cardiovascular events) a few months earlier.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03926117 Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition Phase 2 Interventional Novo Nordisk A/S
NCT04626505 Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan. Phase 2 Interventional Novo Nordisk A/S
NCT03126318 A Study of Patients With Chronic Kidney Disease to Assess the Safety of a Single Dose of COR-001 Phase 1 Interventional University of Colorado, Denver
NCT01559103 Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients Phase 1 Interventional Novo Nordisk A/S
NCT02868229 Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001 Phase 1/Phase 2 Interventional Novo Nordisk A/S 4
NCT06200207 A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation Phase 3 Interventional Novo Nordisk A/S The ATHENA study; stopped early (September 2026) due to predicted lack of efficacy
NCT05021835 ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation Phase 3 Interventional Novo Nordisk A/S The ZEUS study: In July 2026, Novo Nordisk announced that the primary endpoint was missed in this study. There was no significant reduction in major adverse cardiovascular events in participants with atherosclerotic cardiovascular disease, chronic kidney disease (CKD) and inflammation who received ziltivekimab compared to the palcebo cohort. 3,5
NCT06118281 ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack Phase 3 Interventional Novo Nordisk A/S The ARTEMIS study
NCT05636176 A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation Phase 3 Interventional Novo Nordisk A/S The HERMES study; stopped early (September 2026) due to predicted lack of efficacy